Leflunomide 10 milligram (mg) (DrugBank: Leflunomide)
10 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
11 | Myasthenia | 0 |
40 | Takayasu arteritis | 0 |
46 | Malignant rheumatoid arthritis | 1 |
49 | Systemic lupus erythematosus | 0 |
53 | Sjogren syndrome | 0 |
66 | IgA nephropathy | 0 |
162 | Pemphigoid | 0 |
224 | Purpura nephritis | 0 |
271 | Ankylosing spondylitis | 0 |
300 | IgG4-related disease | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03649061 (ClinicalTrials.gov) | June 8, 2018 | 30/7/2018 | COBRA-Slim With or Without Fast Access to TNF Blockade for Remission Induction in Early RA | Effectiveness of a Combination of Methotrexate and a Step Down Glucocorticoid Regimen (COBRA-Slim) for Remission Induction in Patients With Early Rheumatoid Arthritis (RA), With or Without Fast Access to 24 Weeks of Tumor Necrosis Factor (TNF) Blockade in Insufficient Responders, a Randomized, Multicenter, Pragmatic Trial | Arthritis, Rheumatoid | Drug: Etanercept 50 MG/ML;Drug: Leflunomide 10 milligram (MG) | P. Verschueren | Belgium Health Care Knowledge Centre | Active, not recruiting | 18 Years | N/A | All | 284 | Phase 4 | Belgium |